Rockstar Breakfast and Networking
#WESTorg

Are you looking for an opportunity to network with local senior women leaders? If so, this is THE event for you. Enjoy a light breakfast accompanied by lots of conversation with Michal Preminger, Head, Johnson & Johnson Innovation Boston and Sandra Glucksmann, President and CEO, Cedilla Therapeutics. Registration is for WEST MEMBERS ONLY and will be limited to a maximum of 20 participants to ensure an intimate experience. 

Learn more about the Rockstars 

Michal Preminger joined Johnson & Johnson in August 2018 as Head of Johnson & Johnson Innovation Boston. In this role, she leads the Boston innovation center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices. Until recently, Michal served as the Executive Director of Harvard University’s Office of Technology Development (OTD) Harvard Medical School site, where she was responsible for development and commercialization of technologies emerging from research at HMS laboratories and for the strategy and execution of all industry collaborations. Prior to joining Harvard University’s OTD in 2005, Michal held a number of business development and technology development positions at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company’s emerging drug discovery pipeline. Previously, she worked in the technology industry in marketing and business development roles, and co-founded a biotechnology startup. Michal serves on the Scientific Advisory Boards FutuRx Accelerator, and was, until recently, a member of the SAB of Prize4Life and a Member of the Board of Directors of a number of companies, including Compugen, BioArray Genetics, ElmindA and Alma Lasers. She holds a Ph.D. in Biological Sciences from the Weizmann Institute of Science, an MBA from INSEAD, Fontainebleau, France, and a bachelor degree in Medicine from Hadassah Medical School, Hebrew University, Jerusalem. 

Sandra Glucksmann is presently President and CEO of Cedilla Therapeutics. She is a veteran biopharma executive and experienced scientist who most recently served as founder and chief operating officer of the gene editing company Editas Medicine, Inc. She previously served as senior vice president of research and development at Cerulean Pharma, which she also joined at its founding. Sandra was a founding scientist at Millennium Pharmaceuticals, where she spent 13 years, taking on a series of senior roles on the science team before moving into an executive position with responsibility for strategic program management and operations. Sandra serves on the boards of directors of REGENXBIO and Scenic Biotech. Sandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago. She was a post-doctoral fellow at MIT.